Topic: Qrxpharma Ltd.
By Sheena Lee. . Spectrum Pharmaceuticals (SPPI). . Irvine-California based Spectrum is getting a lot of attention lately as promising pipeline...
Combination of Morphine plus Oxycodone IV Demonstrates Improved Analgesia and Tolerability Compared to IV Morphine. QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus ...
QRxPharma reported today positive outcomes of its European Scientific Advice meetings on the development and registration of MoxDuo IR, an immediate release Dual-Opioid(TM) pain therapy. QRxPharma intends to submit a Marketing Authorisation Application (MAA) in Europe, the second largest market (approximately ...
QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and ...
Data Demonstrate Dual-Opioid(TM) Provides Significantly Better Pain Relief Compared to Component Doses; Study Goals and Secondary Endpoints Met. QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. "While the initial ...
PK), a clinical stage Australian pharma, to develop MoxDuo IV for the China market. China Aoxing will fund development of MoxDuo IV for the China market in exchange for exclusive marketing rights of the product in China. QRxPharma will retain ownership of ...
Pain relieving effects of MoxDuo(TM) IR are dose-related with a better safety profile than Percocet in patients with post-operative pain following total knee replacement. QRXPY) announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile ...
Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer May 19 RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer May 19 Transgene Announces Promising Phase I Preliminary Results ...
QRxPharma Limited , a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today additional Phase 3 data for Q8003IR establishing a 12mg/8mg morphine and oxycodone combination as the preferred ...
QRxPharma Limited , a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today initial Phase 3 efficacy results for Q8003IR, an immediate release dual-opioid product intended for the acute management ...
